No Data
Jiangsu Kanion Pharmaceutical (600557.SH): Has not yet been involved in the health and wellness industry.
On December 20, Gelonghui reported that Jiangsu Kanion Pharmaceutical (600557.SH) stated on the investor interaction platform that the company actively serves the macroeconomic strategy of aging population countries. Relying on the advantages of Traditional Chinese Medicine, it focuses on the health needs of elderly people, possessing core products in areas related to aging diseases such as cardiovascular and cerebrovascular diseases, and orthopedic diseases. Additionally, it is conducting research and layout in the treatment areas of aging-related diseases such as Alzheimer's disease, functional constipation, and chronic obstructive pulmonary disease, with related products already in preclinical or clinical stages. The company has not yet ventured into the health care industry.
HAITONG SEC: The trend of moderate price reductions in the centralized procurement of Traditional Chinese Medicine varieties continues, and the domestic Pharmaceutical industry is expected to usher in a wave of mergers and acquisitions.
HAITONG SEC released a Research Report stating that the gentle trend of price reduction for Traditional Chinese Medicine varieties continues.
China Includes Kanion Pharma's Anti-Constipation Granules in Insurance Drug Catalog
Jiangsu Kanion Pharmaceutical (600557.SH): Some pharmaceutical products of the company have been included in the "National Medical Insurance Directory".
GeLonghui Nov. 29th | jiangsu kanion pharmaceutical (600557.SH) announced that the National Medical Insurance Administration and the Ministry of Human Resources and Social Security have issued the "Notice on Printing and Distributing <National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue (2024)>. According to the notice, Jiangsu Kanion Pharmaceutical Co., Ltd.'s exclusive product Jichuan Decoction Granules was included in the <National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue (2024)> for the first time through negotiation. The company's products Jin Gu Zhi Tong Pain Relief Gel (exclusive product) and Linggui Shugan Granules were adjusted from the negotiation directory to the national medical insurance regular directory this time; Pirfenidone
China Approves Jiangsu Kanion Pharmaceutical's Clinical Trial for Psoriasis Cream
Jiangsu Kanion Pharmaceutical (600557.SH) has received the clinical trial approval notice for KYHY2302 cream.
Jiangsu Kanion Pharmaceutical (600557.SH) announced that the company recently received a Class 1 new chemical drug issued by the National Medical Products Administration.
Jiangsu Kanion Pharmaceutical Co.,Ltd. (SHSE:600557) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
No Data
